The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice

Neuromuscular Disorders

Volumn 21, Issue 8, 2011, Pages 579-589

  Messina, Sonia ^a   Bitto, Alessandra ^b   Aguennouz, M'hammed ^a   Vita, Gian Luca ^a   Polito, Francesca ^a,b   Irrera, Natasha ^b   Altavilla, Domenica ^b   Marini, Herbert ^a   Migliorato, Alba ^a   Squadrito, Francesco ^b   Vita, Giuseppe ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Duchenne muscular dystrophy; Genistein; Mdx mice; Natural supplement; NF B

Indexed keywords

CREATINE KINASE; DIMETHYL SULFOXIDE; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLPREDNISOLONE; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; FORELIMB; MALE; MORPHOLOGY; MOUSE; MUSCLE FUNCTION; MUSCLE NECROSIS; MUSCLE REGENERATION; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SOYBEAN; TREATMENT OUTCOME;

ANIMALS; CREATINE KINASE; DISEASE MODELS, ANIMAL; GENISTEIN; GLUCOCORTICOIDS; MALE; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; NF-KAPPA B; OXIDATIVE STRESS; PROTEIN KINASE INHIBITORS; REGENERATION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960929744     PISSN: 09608966     EISSN: 18732364     Source Type: Journal    
DOI: 10.1016/j.nmd.2011.04.014     Document Type: Article

References (51)

1. Dubowitz V. Muscle disorders in childhood 1995, W.B. Saunders. 2nd ed.
2. Emery E.H. The muscular dystrophies. Lancet 2002, 23:687-695.
3. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005, 288:345-353.
4. Nagaraju K., Willmann R. Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on " Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27-28, 2007 and Zürich, June 30-July 1, 2008; TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network. Neuromuscul Disord 2009, 19:502-506.
5. Connolly A.M., Keeling R.M., Mehta S., Pestronk A., Sanes J.R. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 2001, 11:703-712.
6. Granchelli J.A., Pollina C., Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000, 10:235-239.
7. Tidball J.G., Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007, 102:1677-1686.
8. Messina S., Altavilla D., Aguennouz M., et al. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am J Pathol 2006, 168:918-926.
9. Messina S., Bitto A., Aguennouz M., et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp Neurol 2006, 198:234-241.
10. Messina S., Bitto A., Aguennouz M., et al. Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone. Exp Neurol 2009, 220:349-358.
11. Buetler T.M., Renard M., Offord E.A., Schneider H., Ruegg U.T. Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. Am J Clin Nutr 2002, 75:749-753.
12. Hnia K., Gayraud J., Hugon G., et al. l-Arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am J Pathol 2008, 172:1509-1519.
13. Lee J., Burckart G.J. Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol 1998, 38:981-993.
14. Karin M., Delhase M. The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signaling. Semin Immunol 2000, 12:85-98.
15. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001, 81:807-869.
16. Bhat N.R., Zhang P., Lee J.C., Hogan E.L. Extracellular signal regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci 1998, 18:1633-1641.
17. Kolodziejczyk S.M., Walsh G.S., Balazsi K., et al. Activation of JNK1 contributes to dystrophic muscle pathogenesis. Curr Biol 2001, 11:1278-1282.
18. Hnia K., Hugon G., Rivier F., et al. Modulation of p38 mitogen-activated protein kinase cascade and metalloproteinase activity in diaphragm muscle in response to free radical scavenger administration in dystrophin-deficient Mdx mice. Am J Pathol 2007, 170:633-643.
19. Thaloor D., Miller K.J., Gephart J., Mitchell P.O., Pavlath G.K. Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 1999, 277:320-329.
20. Mourkioti F., Kratsios P., Luedde T., et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass, and promotes regeneration. J Clin Invest 2006, 116:2945-2954.
21. Acharyya S., Villalta S.A., Bakkar N., et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007, 117:889-901.
22. Bushby K., Muntoni F., Urtizberea A., Hughes R., Griggs R. Report on the 124th ENMC international workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids, April 2-4, 2004, Naarden, The Netherlands. Neuromuscul Disord 2004, 14:526-534.
23. Manzur A.Y., Kuntzer T., Pike M., Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Sys Rev 2008, CD003725.
24. Wissink S., van Heerde E.C., vand der Burg B., van der Saag P.T. A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids. Mol Endocrinol 1998, 12:355-363.
25. St-Pierre S.J., Chakkalakal J.V., Kolodziejczyk S.M., et al. Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 2004, 18:1937-1939.
26. Monici M.C., Aguennouz M., Mazzeo A., Messina C., Vita G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003, 60:993-997.
27. Cai Q., Rahn R.O., Zhang R. Dietary flavonoids, quercetin, luteolin and genistein, reduce oxidative DNA damage and lipid peroxidation and quench free radicals. Cancer Lett 1997, 119:99-107.
28. Hämäläinen M., Nieminen R., Vuorela P., Heinonen M., Moilanen E. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007, 45673.
29. Choi C., Cho H., Park J., Cho C., Song Y. Suppressive effects of genistein on oxidative stress and NFkappaB activation in RAW 264.7 macrophages. Biosci Biotechnol Biochem 2003, 67:1916-1922.
30. Evans M.J., Eckert A., Lai K., Adelman S.J., Harnish D.C. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res 2001, 89:823-830.
31. Kim H., Lee M.J., Kim J.E., et al. Genistein suppresses tumor necrosis factor-alpha-induced proliferation via the apoptotic signaling pathway in human aortic smooth muscle cells. J Agric Food Chem 2010, 58:2015-2019.
32. Kong A.N., Owuor E., Yu R., et al. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab Rev 2001, 33:255-271.
33. Seibel J., Molzberger A.F., Hertrampf T., Laudenbach-Leschowski U., Diel P. Oral treatment with genistein reduces the expression of molecular and biochemical markers of inflammation in a rat model of chronic TNBS-induced colitis. Eur J Nutr 2009, 48:213-220.
34. Magee P.J., Rowland I.R. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 2004, 91:513-531.
35. Xu S.Z., Zhong W., Ghavideldarestani M., Saurabh R., Lindow S.W., Atkin S.L. Multiple mechanisms of soy isoflavones against oxidative stress-induced endothelium injury. Free Radic Biol Med 2009, 47:167-175.
36. Siow R.C., Li F.Y., Rowlands D.J., de Winter P., Mann G.E. Cardiovascular targets for estrogens and phytoestrogens: transcriptional regulation of nitric oxide synthase and antioxidant defense genes. Free Radic Biol Med 2007, 42:909-925.
37. Kuiper G.G., Lemmen J.G., Carlsson B., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor. Endocrinology 1998, 139:4252-4263.
38. Marini H., Minutoli L., Polito F., et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann Intern Med 2007, 146:839-847.
39. Hamilton-Reeves J.M., Vazquez G., Duval S.J., Phipps W.R., Kurzer M.S., Messina M.J. Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: results of a meta-analysis. Fertil Steril 2010, 94:997-1007.
40. Ullmann U., Metzner J., Frank T., Cohn W., Riegger C. Safety, tolerability, and pharmacokinetics of single ascending doses of synthetic genistein (Bonistein) in healthy volunteers. Adv Ther 2005, 22:65-78.
41. De Luca A., Nico B., Rolland J.F., et al. Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 2008, 32:243-253.
42. Spurney C.F., Gordish-Dressman H., Guerron A.D., et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39:591-602.
43. van Putten M., de Winter C., van Roon-Mom W., van Ommen G.J., 't Hoen P.A., Aartsma-Rus A. A 3 months mild functional test regime does not affect disease parameters in young mdx mice. Neuromuscul Disord 2010, 20:273-280.
44. Grounds M.D., Torrisi J. Anti-TNF-α (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004, 18:668-682.
45. Baltgalvis K.A., Greising S.M., Warren G.L., Lowe D.A. Estrogen regulates estrogen receptors and antioxidant gene expression in mouse skeletal muscle. PLoS One 2010, 13:e10164.
46. Williams C.M., Coleman J.W. Induced expression of mRNA for IL-5, IL-6, TNF-alpha, MIP-2 and IFN-gamma in immunologically activated rat peritoneal mast cells: inhibition by dexamethasone and cyclosporin A. Immunology 1995, 86:244-249.
47. Helferich W.G., Andrade J.E., Hoagland M.S. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology 2008, 16:219-226.
48. Mau M., Kalbe C., Viergutz T., Nürnberg G., Rehfeldt C. Effects of dietary isoflavones on proliferation and DNA integrity of myoblasts derived from newborn piglets. Pediatr Res 2008, 63:39-45.
49. Rehfeldt C., Kalbe C., Nürnberg G., Mau M. Dose-dependent effects of genistein and daidzein on protein metabolism in porcine myotube cultures. J Agric Food Chem 2009, 57:852-857.
50. D'Anna R., Cannata M.L., Marini H., et al. Effects of the phytoestrogen genistein on hot flushes, endometrium, and vaginal epithelium in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled study. Menopause 2009, 16:301-306.
51. de Souza P.L., Russell P.J., Kearsley J.H., Howes L.G. Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutr Rev 2010, 68:542-555.